Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseases
Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic ...
pharmaphorum7y
Novo Nordisk board member quits over NASH conflict of interest
Novo Nordisk board member Mary Szela has quit to avoid a conflict of interest, after the biotech she runs began developing a rival drug for fatty liver disease ... in NASH scores over baseline ...
Fatty liver disease without symptoms? Here’s how to catch it before it is too late
Non-alcoholic fatty liver disease has no early signs. Is your liver at risk? Expert reveals these simple tests could save your life!
Medscape14d
How Should We Manage Patients With Non-alcoholic Fatty Liver Disease in 2007?
Unfortunately, however, little is known about effects of changes in dietary composition on liver histopathology in ... over study in seven patients with NASH has shown that oligofructans given ...
Hosted on MSN1y
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
Novo Nordisk and Eli Lilly are testing their respective blockbuster weight loss injections as treatments for the same kind of liver disease, called nonalcoholic steatohepatitis, or NASH.